Study shows Sanofi's diabetes drug Toujeo halves hypoglycemia risk

12 June 2017

French pharma major Sanofi (Euronext: SAN) has announced new data on its long-acting insulin Toujeo (insulin glargine 300 Units/mL) at the American Diabetes Association (ADA) 77th Scientific Sessions Annual Meeting in San Diego.

The DELIVER 3 retrospective observational study compared switching to Toujeo to switching with another basal insulin including Sanofi’s older treatment, Lantus (insulin glargine 100 Units/mL), and NovoNordisk’s (NOV: N) Levemir (insulin detemir) and Tresiba (insulin degludec), in an at-risk population of older adults with type 2 diabetes.

"Observational real-world data such as DELIVER 3 can contribute to clinical decision-making, helping physicians to better advise their patients"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK